Arteriosclerosis and Thrombosis, Vol 14, 815-823, Copyright © 1994 by American Heart Association

ARTICLES

Stimulation of PAI-1 expression in endothelial cells by cultured vascular smooth muscle cells

M Gallicchio, S Argyriou, G Ianches, EL Filonzi, H Zoellner, JA Hamilton, K McGrath and J Wojta
Department of Diagnostic Haematology, Royal Melbourne Hospital, Victoria, Australia.

Regulation of endothelial cell (EC) plasminogen activator inhibitor type-1 (PAI-1), the primary physiological inhibitor of tissue-type plasminogen activator (TPA) and urokinase-type plasminogen activator (UPA), by various stimuli has been well characterized. We report the upregulation of secreted and intracellular PAI-1 in human umbilical ECs when cocultured with human smooth muscle cells (SMCs) on amniotic membranes or incubated with SMC conditioned medium (CM) under serum- free conditions as determined by enzyme-linked immunosorbent assay. Cocultured human umbilical vein ECs and SMCs, or human umbilical artery ECs and SMCs, displayed a 73% and 68% increase, respectively, in released PAI-1. SMC-derived stimulatory factor release showed tissue specificity, since only human aortic, umbilical vein, and umbilical artery SMCs upregulated PAI-1 synthesis, whereas SMCs from human mammary artery, pulmonary artery, and saphenous vein did not. Stimulation of EC PAI-1 by SMC CM was both time and concentration dependent, with as much as five- and fourfold increases in supernatants and lysates, respectively. PAI-1 synthesis and activity in ECs from other vascular beds were also upregulated by SMC CM. Northern blot analysis paralleled the protein results, showing as much as a 2.7-fold increase in specific EC PAI-1 mRNA expression after incubation with SMC CM for 8 hours. PAI-1 stimulatory activity in SMC CM was completely abolished by boiling or incubation with protamine sulfate and was reduced by transient acidification or heparin-Sepharose pretreatment by 33% or 48%, respectively. The stimulatory factor(s) appeared to have a molecular mass of 23 kD as determined by gel filtration.(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				C. E. Hafer-Macko, F. M. Ivey, J. D. Sorkin, and R. F. Macko Microvascular tissue plasminogen activator is reduced in diabetic neuropathy Neurology, July 17, 2007; 69(3): 268 - 274. [Abstract] [Full Text] [PDF]

				J. M. Edelberg, P. D. Christie, and R. D. Rosenberg Regulation of Vascular Bed-Specific Prothrombotic Potential Circ. Res., July 20, 2001; 89(2): 117 - 124. [Abstract] [Full Text] [PDF]

				H. P. Kohler and P. J. Grant Plasminogen-Activator Inhibitor Type 1 and Coronary Artery Disease N. Engl. J. Med., June 15, 2000; 342(24): 1792 - 1801. [Full Text] [PDF]

				R. D. Rosenberg and W. C. Aird Vascular-Bed-Specific Hemostasis and Hypercoagulable States N. Engl. J. Med., May 20, 1999; 340(20): 1555 - 1564. [Full Text] [PDF]

				P. Kauhanen, V. Siren, O. Carpen, A. Vaheri, M. Lepantalo, and R. Lassila Plasminogen Activator Inhibitor-1 in Neointima of Vein Grafts : Its Role in Reduced Fibrinolytic Potential and Graft Failure Circulation, September 16, 1997; 96(6): 1783 - 1789. [Abstract] [Full Text]

				G. Christ, P. Hufnagl, C. Kaun, G. Mundigler, G. Laufer, K. Huber, J. Wojta, and B. R. Binder Antifibrinolytic Properties of the Vascular Wall: Dependence on the History of Smooth Muscle Cell Doublings In Vitro and In Vivo Arterioscler Thromb Vasc Biol, April 1, 1997; 17(4): 723 - 730. [Abstract] [Full Text]